Liujiang Pharmaceutical

Chongqing Liujiang Pharmaceutical Technology Co., Ltd. is located in Chongqing Biomedical Industrial Park. Supported by the Chongqing Municipal People's Government, it was jointly invested and established on September 15, 2015 by Chongqing Zhien Pharmaceutical Co., Ltd. and Chongqing Maliu Yanjiang Development Investment Co., Ltd. The company aims to lead and drive pharmaceutical enterprises in Southwest China and even nationwide to achieve international development from high-end generic drugs to new drug research and development. It is currently the only CRO platform in Chongqing that can provide a one-stop closed-loop service covering generic drug pharmaceutical research, bioanalytical testing and clinical trials, production transfer, and registration application. The platform serves domestic and overseas markets, integrates global advantageous resources, and strives to build a domestic first-class and even internationally influential international high-end drug introduction, cultivation and industrialization technology service platform. In recent years, the company has successively won honors such as "New Enterprise R&D Institution" from the Chongqing Economic and Information Commission, "Chongqing's First Generic Drug Quality and Efficacy Consistency Evaluation Center," and "High-tech Service" and "Innovation and Entrepreneurship Demonstration Team" from the Municipal Science and Technology Commission. The company has 11,000 square meters of modern pharmaceutical R&D laboratories, with a total investment of nearly 100 million yuan; it is equipped with advanced scientific research instruments and equipment worth more than 50 million yuan, and its technical performance has reached the leading level. In terms of synthesis, it has double-layer glass reactors (30L, 50L), rotary evaporators, reactor high-low temperature circulators, etc.; in terms of formulations, it has wet granulators, dry granulators, crushers and sizing machines, fluid bed granulators, multi-motion mixers, tablet presses, coating machines, capsule filling machines, blister packaging machines (aluminum-plastic, aluminum-aluminum), fully automatic sampling dissolution testers, jet mills, Malvern particle size analyzers, etc.; in terms of analysis, it has HPLC, GC, LC-MS, GC-MS, atomic absorption, preparative liquid chromatography, semi-preparative liquid chromatography, ion chromatography, etc.; the configuration of the above advanced instruments and equipment provides a favorable guarantee for pharmaceutical R&D with excellent quality, high efficiency, and controllable quality. The company has built and strengthened network security, data security, software and hardware equipment validation (3Q), emergency plans (24-hour uninterrupted power system), a complete set of standardized operating procedures (from employee training, experimental operations, experimental record report writing, etc.), quality assurance system, and an efficient and high-quality project management system. We also have a bioanalytical department dedicated to biological blood sample analysis and testing, equipped with AB Company triple quadrupole 6500+ mass spectrometer, Shimadzu UPLC LC-30A, temperature-controlled centrifuges, vortex oscillators and other high-end instruments for biological blood sample testing and analysis. The chief scientist of biological blood sample analysis and testing is a well-known analysis and business management expert who returned from abroad to start a business. The company currently has a high-quality management team with an international perspective, and a project R&D team composed of technical personnel with many years of industry work experience. The company currently has 160 professional technical and management personnel in various fields such as medicinal chemistry, analysis, formulation, biology, pharmacology, and registration application, with more than 84% holding bachelor's degrees or above, and more than 85% being R&D personnel. Chongqing Liujiang Pharmaceutical Technology Co., Ltd. recently mainly serves the quality and efficacy consistency evaluation of generic drugs, and later will expand to support generic drugs and new drug research and development, with the development purpose of leading and driving a group of Chongqing pharmaceutical enterprises to achieve internationalization of high-end generic drugs, integrating global advantageous resources, facing domestic and overseas markets, and striving to build a domestic first-class and internationally influential international high-end drug introduction, cultivation and industrialization technology service platform.